metoprolol has been researched along with Diabetes Mellitus, Adult-Onset in 49 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension." | 9.11 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Oakes, R; Phillips, RA; Raskin, P; Wright, JT, 2004) |
| "To compare the long-term effects of the angiotensin-converting enzyme (ACE)-inhibitor quinapril and the cardioselective beta-adrenergic blocking agent metoprolol on glycaemic control, with glycosylated haemoglobin (HbA1c) as the principal variable, in non-insulin-dependent diabetes mellitus (NIDDM) patients with hypertension." | 9.08 | Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group. ( Asplund, K; Bystedt, T; Dahlöf, B; Jern, S; Kjellström, T; Lithell, H; Ostman, J, 1998) |
| "The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients less than or equal to 75 years of age, with borderline to moderate primary hypertension." | 9.07 | Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. ( Beck-Nielsen, H; Faergeman, O; Gall, MA; Gerdes, LU; Hommel, E; Lauritzen, M; Mathiesen, ER; Rossing, P; Skøtt, P; Vølund, A, 1992) |
| "To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure." | 9.06 | Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. ( Anderson, NM; Cruickshank, JK; Jepson, E; Wadsworth, J; Young, SM, 1988) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 8.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "To compare efficacy and safety of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease (IHD) combined with type 2 diabetes." | 7.72 | [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. ( Akhmedova, OO; Buval'tsev, VI; Gavrilov, IuV; Makolkin, VI; Petriĭ, VV, 2003) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 6.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days I and S." | 5.36 | [Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus]. ( Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO, 2010) |
| "ER metoprolol was then added to their ongoing therapy." | 5.35 | Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients. ( Falkner, B; Kushner, H, 2008) |
| " As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed." | 5.34 | [Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension]. ( Frese, T; Sandholzer, H, 2007) |
| " Patients with type 2 diabetes and hypertension on maximal RAS blockade (n=70) were randomized to nebivolol or metoprolol succinate daily." | 5.17 | Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. ( Bakris, G; Briasoulis, A; Flynn, C; Kalaitzidis, R; Lazich, I; Oliva, R; Schlaffer, C, 2013) |
| "This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes." | 5.14 | Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. ( Christiansen, B; Dominguez, H; Hermann, TS; Kveiborg, B; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2010) |
| "We observed a significant increase in ADMA levels, a marker of endothelial dysfunction, during metoprolol treatment, whereas nebivolol had neutral effects on ADMA levels in patients with type 2 diabetes mellitus and hypertension." | 5.12 | Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. ( Fici, F; Hekim, N; Oğuz, A; Uzunlulu, M; Yalçin, Y; Yorulmaz, E, 2007) |
| " The current analysis of the Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial evaluates the effects of carvedilol and metoprolol tartrate on weight gain in patients with type 2 diabetes and hypertension." | 5.12 | Body weight changes with beta-blocker use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bangalore, S; Bell, DS; Fonseca, V; Holdbrook, FK; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months." | 5.12 | Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| "Changes in HbA1c and homeostasis model assessment-insulin resistance (HOMA-IR) were assessed over 5 months, comparing carvedilol with metoprolol tartrate according to insulin sensitizer (TZDs and metformin) use." | 5.12 | Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2007) |
| "Carvedilol resulted in a lower perceived burden of diabetes-related symptoms in patients with type 2 diabetes and hypertension." | 5.12 | beta-blocker use and diabetes symptom score: results from the GEMINI study. ( Anderson, KM; Bakris, GL; Bell, DS; Dalal, MR; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension." | 5.11 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Oakes, R; Phillips, RA; Raskin, P; Wright, JT, 2004) |
| "To compare the long-term effects of the angiotensin-converting enzyme (ACE)-inhibitor quinapril and the cardioselective beta-adrenergic blocking agent metoprolol on glycaemic control, with glycosylated haemoglobin (HbA1c) as the principal variable, in non-insulin-dependent diabetes mellitus (NIDDM) patients with hypertension." | 5.08 | Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group. ( Asplund, K; Bystedt, T; Dahlöf, B; Jern, S; Kjellström, T; Lithell, H; Ostman, J, 1998) |
| "The effects of long-term treatment with captopril and conventional therapy on albuminuria and metabolic parameters were compared in 74 hypertensive type II diabetics with normal serum creatinine." | 5.07 | Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. ( Lacourcière, Y; Nadeau, A; Poirier, L; Tancrède, G, 1993) |
| "The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients less than or equal to 75 years of age, with borderline to moderate primary hypertension." | 5.07 | Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. ( Beck-Nielsen, H; Faergeman, O; Gall, MA; Gerdes, LU; Hommel, E; Lauritzen, M; Mathiesen, ER; Rossing, P; Skøtt, P; Vølund, A, 1992) |
| "To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure." | 5.06 | Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. ( Anderson, NM; Cruickshank, JK; Jepson, E; Wadsworth, J; Young, SM, 1988) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 4.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| " The curative effect of metoprolol tartrate and valsartan in reversing left ventricular hypertrophy in the group positive for autoantibodies was much better than in the negative group." | 3.80 | Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation. ( Xu, C; Xu, J; Zhao, L, 2014) |
| "To compare efficacy and safety of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease (IHD) combined with type 2 diabetes." | 3.72 | [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. ( Akhmedova, OO; Buval'tsev, VI; Gavrilov, IuV; Makolkin, VI; Petriĭ, VV, 2003) |
| "In patients with type 2 diabetes currently receiving a renin-angiotensin blocker, compared with metoprolol tartrate, the addition of carvedilol for blood pressure control resulted in a significant decrease in triglyceride, total cholesterol and non-HDL cholesterol levels." | 2.74 | Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. ( Bakris, GL; Bell, DS; McGill, JB, 2009) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 2.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Subjects with type 2 diabetes experience an increased cardiovascular morbidity and mortality, related to a high prevalence of hypertension, dyslipidemia, and obesity." | 2.71 | Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. ( Gödicke, J; Häring, HU; Helsberg, K; Jacob, S; Klimm, HJ; Rett, K, 2004) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days I and S." | 1.36 | [Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus]. ( Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO, 2010) |
| "ER metoprolol was then added to their ongoing therapy." | 1.35 | Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients. ( Falkner, B; Kushner, H, 2008) |
| " As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed." | 1.34 | [Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension]. ( Frese, T; Sandholzer, H, 2007) |
| "We compared the incidence of type 2 diabetes mellitus (DM) and the composite outcome of impaired fasting glucose or DM (IFG/DM) for the African American Study of Kidney Disease and Hypertension interventions." | 1.33 | Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. ( Agodoa, LY; Appel, LJ; Cheek, D; Contreras, G; Gassman, J; Lash, JP; Miller, ER; Randall, OS; Thornley-Brown, D; Wang, X; Wright, JT, 2006) |
| "Participants with hypertension and type 2 diabetes were randomized to either metoprolol tartrate (n=737) or carvedilol (n=498) in blinded fashion after a washout period of all antihypertensive agents except for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 1.33 | Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, F; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.16) | 18.7374 |
| 1990's | 6 (12.24) | 18.2507 |
| 2000's | 26 (53.06) | 29.6817 |
| 2010's | 8 (16.33) | 24.3611 |
| 2020's | 5 (10.20) | 2.80 |
| Authors | Studies |
|---|---|
| Schwartz, B | 1 |
| Pierce, C | 1 |
| Madelaire, C | 1 |
| Schou, M | 1 |
| Kristensen, SL | 1 |
| Gislason, GH | 1 |
| Køber, L | 2 |
| Torp-Pedersen, C | 2 |
| Andersson, C | 1 |
| Bannister, BE | 1 |
| Parry, DR | 1 |
| Pouliot, JD | 1 |
| Tchernev, G | 1 |
| Bussey, CT | 1 |
| Babakr, AA | 1 |
| Iremonger, RR | 1 |
| van Hout, I | 1 |
| Wilkins, GT | 1 |
| Lamberts, RR | 1 |
| Erickson, JR | 1 |
| Pearson, JT | 1 |
| Thambyah, HP | 1 |
| Waddingham, MT | 1 |
| Inagaki, T | 1 |
| Sukumaran, V | 1 |
| Ngo, JP | 1 |
| Ow, CPC | 1 |
| Sonobe, T | 1 |
| Chen, YC | 1 |
| Edgley, AJ | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Tsuchimochi, H | 1 |
| Shirai, M | 1 |
| Briasoulis, A | 1 |
| Oliva, R | 1 |
| Kalaitzidis, R | 1 |
| Flynn, C | 1 |
| Lazich, I | 1 |
| Schlaffer, C | 1 |
| Bakris, G | 1 |
| Donatelli, NS | 1 |
| Somes, J | 1 |
| Patel, BM | 1 |
| Bhadada, SV | 1 |
| Zhao, L | 1 |
| Xu, C | 1 |
| Xu, J | 1 |
| Chen, RJ | 1 |
| Chu, H | 1 |
| Tsai, LW | 1 |
| Bell, DS | 8 |
| Bakris, GL | 8 |
| McGill, JB | 8 |
| Phillips, RA | 7 |
| Fonseca, V | 7 |
| Katholi, RE | 7 |
| Messerli, FH | 6 |
| Raskin, P | 7 |
| Wright, JT | 8 |
| Iyengar, M | 3 |
| Anderson, KM | 6 |
| Lukas, MA | 7 |
| Galeeva, ZM | 1 |
| Galiavich, AS | 1 |
| Kondrat'ev, AI | 1 |
| Dolgikh, VT | 1 |
| Stotskiĭ, AO | 1 |
| Kveiborg, B | 1 |
| Hermann, TS | 1 |
| Major-Pedersen, A | 1 |
| Christiansen, B | 1 |
| Rask-Madsen, C | 1 |
| Raunsø, J | 1 |
| Dominguez, H | 1 |
| Leung, AA | 1 |
| Ghali, WA | 1 |
| Anguita Sánchez, M | 1 |
| Cruickshank, JM | 1 |
| Makolkin, VI | 1 |
| Akhmedova, OO | 1 |
| Buval'tsev, VI | 1 |
| Gavrilov, IuV | 1 |
| Petriĭ, VV | 1 |
| Jacob, S | 1 |
| Klimm, HJ | 1 |
| Rett, K | 1 |
| Helsberg, K | 1 |
| Häring, HU | 1 |
| Gödicke, J | 1 |
| Oakes, R | 1 |
| Sica, DA | 1 |
| Gonzalez-Feldman, E | 1 |
| Tepliakov, AT | 1 |
| Kuznetsova, AV | 1 |
| Stepacheva, TA | 1 |
| D'iakova, ML | 1 |
| Shilov, SN | 1 |
| Bolotskaia, LA | 1 |
| Messerli, F | 1 |
| Waterhouse, B | 2 |
| Lynch, T | 1 |
| Thornley-Brown, D | 1 |
| Wang, X | 1 |
| Randall, OS | 1 |
| Miller, ER | 1 |
| Lash, JP | 1 |
| Gassman, J | 1 |
| Contreras, G | 1 |
| Appel, LJ | 1 |
| Agodoa, LY | 1 |
| Cheek, D | 1 |
| Dalal, MR | 1 |
| Bank, AJ | 1 |
| Kelly, AS | 1 |
| Thelen, AM | 1 |
| Kaiser, DR | 1 |
| Gonzalez-Campoy, JM | 1 |
| Bangalore, S | 1 |
| Holdbrook, FK | 2 |
| Frese, T | 1 |
| Sandholzer, H | 1 |
| Oğuz, A | 1 |
| Uzunlulu, M | 1 |
| Yorulmaz, E | 1 |
| Yalçin, Y | 1 |
| Hekim, N | 1 |
| Fici, F | 1 |
| Falkner, B | 1 |
| Kushner, H | 1 |
| Menevşe, E | 1 |
| Yee, J | 1 |
| Pacy, PJ | 1 |
| Dodson, PM | 1 |
| Kubicki, AJ | 1 |
| Fletcher, RF | 1 |
| Taylor, KG | 1 |
| Ferlito, S | 1 |
| Del Campo, F | 1 |
| Indelicato, G | 1 |
| Di Vincenzo, S | 1 |
| Fichera, C | 1 |
| La Vignera, A | 1 |
| Sasaki, H | 1 |
| Naka, K | 1 |
| Kishi, Y | 1 |
| Ohoshi, T | 1 |
| Hagihara, T | 1 |
| Matsuo, H | 1 |
| Sowa, R | 1 |
| Matsumoto, G | 1 |
| Sanke, T | 1 |
| Nanjo, K | 1 |
| Gall, MA | 2 |
| Rossing, P | 2 |
| Skøtt, P | 2 |
| Hommel, EE | 1 |
| Mathiesen, ER | 2 |
| Gerdes, LU | 2 |
| Lauritzen, M | 2 |
| Vølund, A | 2 |
| Faergeman, O | 2 |
| Beck-Nielsen, H | 2 |
| Lacourcière, Y | 1 |
| Nadeau, A | 1 |
| Poirier, L | 1 |
| Tancrède, G | 1 |
| Tuominen, JA | 1 |
| Eriksson, JG | 1 |
| Koivisto, VA | 1 |
| Ostman, J | 1 |
| Asplund, K | 1 |
| Bystedt, T | 1 |
| Dahlöf, B | 1 |
| Jern, S | 1 |
| Kjellström, T | 1 |
| Lithell, H | 1 |
| Cleophas, TJ | 1 |
| van Ouwerkerk, BM | 1 |
| van der Meulen, J | 1 |
| Zwinderman, AH | 1 |
| Hommel, E | 1 |
| Odugbesan, O | 1 |
| Toop, M | 1 |
| Barnett, AH | 1 |
| Cruickshank, JK | 1 |
| Anderson, NM | 1 |
| Wadsworth, J | 1 |
| Young, SM | 1 |
| Jepson, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00497003] | Phase 4 | 50 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus[NCT00123604] | Phase 4 | 36 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion. (NCT00123604)
Timeframe: change from baseline to 5 months
| Intervention | percentage of change in dilation (Mean) |
|---|---|
| Carvedilol | 6.2 |
| Metoprolol | 4.1 |
4 reviews available for metoprolol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Beers list: what's NOT on "tap" for the older adult.
Topics: Aged, 80 and over; Antiemetics; Antihypertensive Agents; Arthritis; Chlorpropamide; Confusion; Diabe | 2013 |
Appreciating the medical literature: five notable articles in general internal medicine from 2009 and 2010.
Topics: Aged; Anti-Arrhythmia Agents; Anticholesteremic Agents; Atrial Fibrillation; Blood Pressure; Cardiov | 2011 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
23 trials available for metoprolol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converti | 2013 |
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Press | 2008 |
[Efficacy and tolerability of metoprolol retard in the treatment of patients with arterial hypertension and ischemic heart disease combined with type 2 diabetes mellitus].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2009 |
Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Dose-Respon | 2010 |
Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2004 |
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2004 |
Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; C | 2005 |
[Antiischemic and metabolic effects of nebivolol and metaprolol CR/XL (betalok ZOK) in patients with postinfarction heart dysfunction].
Topics: Adrenergic beta-Antagonists; Benzopyrans; Blood Glucose; Coronary Angiography; Coronary Circulation; | 2005 |
beta-blocker use and diabetes symptom score: results from the GEMINI study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cognition; Diab | 2007 |
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Double-Blind Metho | 2007 |
Body weight changes with beta-blocker use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Body Weight; C | 2007 |
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2007 |
Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Arginine; Benzopyrans; Biomarkers; B | 2007 |
[The effect of captopril, metoprolol and hydrochlorothiazide therapy in patients with non-insulin-dependent diabetes (NIDDM) and primary hypertension. A double-blind, randomized cross-over study].
Topics: Aged; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evaluation; Female; Humans; Hy | 1993 |
Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.
Topics: Aged; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1993 |
Acute administration of metoprolol and enalaprilat reduces insulin-stimulated thermogenesis and skin blood flow.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure | 1996 |
Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 1998 |
Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2001 |
Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension.
Topics: Aged; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; | 1992 |
Beta-and alpha-adrenergic blockade and metabolic responses to insulin induced hypoglycaemia in diabetics.
Topics: Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Acids, Non | 1987 |
Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol.
Topics: Aged; Albuminuria; Black or African American; Clinical Trials as Topic; Diabetes Mellitus, Type 2; D | 1988 |
22 other studies available for metoprolol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study.
Topics: Aged; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Metoprolo | 2021 |
Clinically Significant Bradycardia and Hypotension Following Consumption of Betel Leaf in a Patient Treated for Chronic Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Bradycardia; Diabetes Mellitus, Type 2; Female; Humans; Hypotension; Meto | 2023 |
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND ТHE SUBSEQUENT SKIN CANCER DEVELOPMENT
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2023 |
Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Animals; Carvedilol; Coronary Artery Bypass; Diabetes | 2020 |
β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carvedilol; Coronary A | 2021 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation.
Topics: Aged; Antihypertensive Agents; Autoantibodies; Biomarkers; Diabetes Mellitus, Type 2; Dilatation, Pa | 2014 |
Impact of Beta-Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population-Based Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Dat | 2017 |
[Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Benzazepines; Diabetes Mellitus, Type 2 | 2010 |
[Moxonidine is advantageous for hypertensive type 2 diabetic patients. Therapy of hypertension also lowers HbA1c].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; H | 2003 |
[Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Benzopyrans; Carbohydrate Met | 2003 |
Carvedilol, metoprolol, and insulin resistance.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Humans; Hypertension; In | 2005 |
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Carbazoles | 2005 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and C | 2006 |
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Antihypertensive Agents; Black or African American; | 2006 |
[Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiop | 2008 |
Effect of nebivolol and metoprolol treatments on serum asymmetric dimethlyarginine levels in hypertensive patients with type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Arginine; Benzopyrans; Confounding Factors, Epidemiologic; Diabetes Mel | 2008 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
Comparison of the hypotensive and metabolic effects of metoprolol therapy with a high fibre, low sodium, low fat diet in hypertensive type 2 diabetic subjects.
Topics: Blood Pressure; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, S | 1984 |
Blood glycerol levels in type-2 diabetics after beta-1-blockade and alpha-2 adrenergic stimulation.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Clonidine; Diabetes Mellitus, T | 1984 |
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
Topics: Adult; Aged; Atenolol; Carteolol; Diabetes Mellitus, Type 2; Diltiazem; Enalapril; Female; Glucose; | 1994 |